SWOG clinical trial number
CTSU/C80702
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer
Closed
Phase
Abbreviated Title
Ph III Colon FOLFOX + Celecoxib/Placebo
Status Notes
This study will be permanently closed to accrual effective 11/20/15 at 4:30 P.M. E.S.T..
Activated
08/15/2010
Closed
11/20/2015
Participants
CTSU
Research committees
Gastrointestinal Cancer
Treatment
5-Fluorouracil
Leucovorin Calcium
Oxaliplatin
Celecoxib
Placebo
Eligibility Criteria Expand/Collapse
The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.
Publication Information Expand/Collapse
2023
Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
PMid: PMID35944235 | PMC number: PMC9839249
PMid: PMID36701146
PMid: PMID36367997 | PMC number: PMC9928634
2021
PMid: PMID33821899 | PMC number: PMC8025124
PMid: PMID34752136 | PMC number: PMC8677996
2020
2018
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
PMid: PMID29590544 | PMC number: PMC6426127
PMid: PMID29438451 | PMC number: PMC6864492
2017
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
2013
PMid: PMID24032000 | PMC number: PMC3766516
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
31%
Open
Phase
SWOG Clinical Trial Number
S2104
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
12%
Open
Phase